Abstract：
Chronic hepatitis B and C are among the most significant infectious diseases worldwide, and are major risk factors for liver cirrhosis and liver cancer. In Japan, comprehensive hepatitis measures are implemented for the testing and treatment of viral hepatitis, thus enabling the early diagnosis of liver cancer. Nevertheless, patients with decompensated cirrhosis and liver cancer often have unfavorable prognoses and require repetitive long-term treatment. In fiscal year 2018, an integrated policy of medical expense subsidies and research was established in Japan that aimed to alleviate patients\' financial burden and launch the clinical registry of advanced liver disease. Over time, updates to the eligibility for the subsidy increased access to patients and has led to an increased number of beneficiaries. Additionally, the accumulation of clinical data in the registry has revealed the treatment choices for these diseases. However, the disparities in efforts across prefectures have also become evident. Raising public awareness of the policy and tightening the multisector healthcare network are keys to success in supporting qualifying patients with advanced liver disease.
摘要：
慢性乙型和丙型肝炎是世界上最重要的传染病之一，是肝硬化和肝癌的主要危险因素。在日本,实施全面的肝炎措施来检测和治疗病毒性肝炎，从而使肝癌的早期诊断。然而，失代偿期肝硬化和肝癌患者往往预后不良,需要反复长期治疗.2018财年，日本制定了医疗费用补贴和研究综合政策，旨在减轻患者的经济负担，并启动晚期肝病的临床登记。随着时间的推移,获得补贴资格的最新情况增加了患者的机会，并导致受益人人数增加。此外,注册中临床数据的积累揭示了这些疾病的治疗选择。然而,各州之间的努力差异也越来越明显。提高公众对该政策的认识和加强多部门医疗保健网络是成功支持符合资格的晚期肝病患者的关键。
